Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Lainie Martin
NRG Oncology
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
28 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Providence Saint Joseph Medical Center/disney Family Cancer Center
Burbank, California, United States
- the Hospital of Central Connecticut
New Britain, Connecticut, United States
- Florida Hospital Orlando
Orlando, Florida, United States
- University of Chicago Comprehensive Cancer Center
Chicago, Illinois, United States
- Mcfarland Clinic Pc-William R Bliss Cancer Center
Ames, Iowa, United States
- Iowa Lutheran Hospital
Des Moines, Iowa, United States
- Iowa Methodist Medical Center
Des Moines, Iowa, United States
- Iowa-Wide Oncology Research Coalition Ncorp
Des Moines, Iowa, United States
- Medical Oncology and Hematology Associates-Des Moines
Des Moines, Iowa, United States
- Medical Oncology and Hematology Associates-Laurel
Des Moines, Iowa, United States
- Mercy Medical Center - Des Moines
Des Moines, Iowa, United States
- University of Iowa/holden Comprehensive Cancer Center
Iowa City, Iowa, United States
- Washington University School of Medicine
St Louis, Missouri, United States
- Nebraska Methodist Hospital
Omaha, Nebraska, United States
- Cooper Hospital University Medical Center
Camden, New Jersey, United States
- Carolinas Medical Center/levine Cancer Institute
Charlotte, North Carolina, United States
- Novant Health Presbyterian Medical Center
Charlotte, North Carolina, United States
- Duke University Medical Center
Durham, North Carolina, United States
- Summa Akron City Hospital/cooper Cancer Center
Akron, Ohio, United States
- Case Western Reserve University
Cleveland, Ohio, United States
- Riverside Methodist Hospital
Columbus, Ohio, United States
- Lake University Ireland Cancer Center
Mentor, Ohio, United States
- University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States
- Abington Memorial Hospital
Abington, Pennsylvania, United States
- Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
- Women and Infants Hospital
Providence, Rhode Island, United States
- Baylor All Saints Medical Center at Fort Worth
Fort Worth, Texas, United States
- Carilion Clinic Gynecological Oncology
Roanoke, Virginia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Oct 2010
- Primary completion
- 31 Jul 2012
- Completion
- 31 Jul 2014
- Last update posted
- 7 Sept 2017
- Registered enrollment
- 31
- Registry id
- NCT01039207
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.